MetLife Investment Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

MetLife Investment Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01M	Buy	68,122 +1,494	+2%	+$21.8K	0.01%	1388
2025 Q4	$1.06M	Sell	66,628 -4,192	-6%	-$59.4K	0.01%	1393
2025 Q3	$783K	Sell	70,820 -3,481	-5%	-$38K	﹤0.01%	1591
2025 Q2	$629K	Sell	74,301 -9,507	-11%	-$76.2K	﹤0.01%	1571
2025 Q1	$674K	Sell	83,808 -1,872	-2%	-$15.2K	﹤0.01%	1556
2024 Q4	$769K	Buy	85,680 +2,918	+4%	+$23.8K	﹤0.01%	1557
2024 Q3	$607K	Hold	82,762	–	–	﹤0.01%	1671
2024 Q2	$473K	Buy	82,762 +11,561	+16%	+$60.9K	﹤0.01%	1745
2024 Q1	$357K	Hold	71,201	–	–	﹤0.01%	1863
2023 Q4	$640K	Hold	71,201	–	–	﹤0.01%	1544
2023 Q3	$553K	Hold	71,201	–	–	﹤0.01%	1567
2023 Q2	$689K	Hold	71,201	–	–	0.01%	1487
2023 Q1	$780K	Hold	71,201	–	–	0.01%	1366
2022 Q4	$308K	Hold	71,201	–	–	﹤0.01%	1967
2022 Q3	$535K	Hold	71,201	–	–	﹤0.01%	1590
2022 Q2	$716K	Buy	+71,201	New	+$796K	0.01%	1417

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MetLife Investment Management's AUPH Position: Q1 2026 in Review

MetLife Investment Management increased its Aurinia Pharmaceuticals (AUPH) stake by 2.2% in Q1 2026, buying an estimated $21.8K and bringing the position to 68,122 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #1388.

MetLife Investment Management first reported a position in AUPH in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.06M in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

MetLife Investment Management held 68,122 shares of Aurinia Pharmaceuticals worth $1.01M as of Q1 2026.
MetLife Investment Management bought 1,494 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $21.8K.
Aurinia Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1388 holding.
MetLife Investment Management first reported a position in Aurinia Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
MetLife Investment Management's Aurinia Pharmaceuticals position peaked at $1.06M in Q4 2025.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.